Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trialHugues Chabriat, Usman Khan, Claudio L. Bassetti et al.|The Lancet Neurology|2020Cited by 51
COVID-19-associated Guillain-Barré syndrome in the early pandemic experience in Lombardia (Italy)Filippo Martinelli Boneschi, Andrea Salmaggi, Carlo Ferrarese et al.|Neurological Sciences|2022Cited by 9
Covid-19-associated Guillain-Barré syndrome in the first wave of COVID-19 pandemic in Lombardia: Increased incidence or increased seroprevalence?Filippo Martinelli Boneschi, Andrea Salmaggi, Antonio Colombo et al.|Journal of the Neurological Sciences|2021Cited by 0
Correction to: COVID‑19‑associated Guillain‑Barré syndrome in the early pandemic experience in Lombardia (Italy)Filippo Martinelli Boneschi, Andrea Salmaggi, Antonio Colombo et al.|Neurological Sciences|2022Cited by 0